2025 – Page 7 – Talk Bio

EMD Serono Joins TrumpRx in Affordability Push; Roche Launches DTC Program

1 week ago talkbio0Tagged Affordability, CNPV, direct-to-consumer sales, Ditiocarb, Electromechanical dissociation, Fertility Agents, Fertilization in Vitro, Pergoveris, Programs - Publication Format, Roche (company), serono, tariffs, TrumpRx, White House Executive Order

EMD Serono; TrumpRx; IVF therapies; affordability; fertility drugs; Direct-to-Consumer sales; Roche; DTC program; White House Executive Order; Section 232 tariffs; CNPV program; Pergoveris

Connecticut Biotech Veradermics Secures $150M for Phase 3 Trials of Oral Rogaine

1 week ago talkbio0Tagged Biotechnology, Clinical Development, Clinical Trials, Connecticut biotech, Fund Raising, hair loss treatment, Oral cavity, Phase 3, Rogaine, Veradermics

Veradermics; Connecticut biotech; oral Rogaine; Phase 3 clinical trials; fundraising; hair loss treatment; biotechnology; clinical development

White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations

1 week ago talkbio0Tagged AstraZeneca, drug price, Electromechanical dissociation, Fertility Agents, Fertilization in Vitro, Glucagon-Like Peptide 1, Medicaid, Most-Favored-Nation, Pfizer, Pricing, serono, Trump administration, United States Food and Drug Administration, Voucher

most-favored nation pricing; fertility drugs; IVF; Trump administration; drug pricing; Medicaid; FDA vouchers; GLP-1; EMD Serono; Pfizer; AstraZeneca

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

1 week ago talkbio0Tagged Biological Factors, CNS disorder, Praxis Precision Medicines, Pricing, public entity

Praxis Precision Medicines; public offering; $525 million; stock offering; share offering; pricing; biopharmaceutical; central nervous system disorders

Friday Five: ESMO Looms Large, Arcus’ TIGIT Revival, and J&J’s Myeloma Advances

1 week ago talkbio0Tagged 2025, Arcus Biosciences, domvanalimab, ESMO, gastroesophageal adenocarcinoma, immuno-oncology, J&J, Multiple Myeloma, oncology clinical trials, Substance with programmed cell death protein 1 inhibitor mechanism of action (substance), TIGIT antibody, zimberelimab

ESMO 2025; Arcus Biosciences; domvanalimab; TIGIT antibody; gastroesophageal adenocarcinoma; J&J; multiple myeloma; immuno-oncology; PD-1 inhibitor; zimberelimab; oncology clinical trials

Sanofi Partners with EVOQ Therapeutics to Advance NanoDisc-Based Autoimmune Therapies

1 week ago talkbio0Tagged Autoimmune Diseases, Celiac Disease, Diabetes Mellitus, Insulin-Dependent, EVOQ, Immune Tolerance, License Agreement, Lupus Vulgaris, MOG antibody disease, NanoDisc, Rheumatoid Arthritis, sanofi

Sanofi; EVOQ Therapeutics; NanoDisc; autoimmune disease; license agreement; immune tolerance; celiac disease; type 1 diabetes; MOG antibody disease; rheumatoid arthritis; lupus

Merck & Co. Announces Keytruda Achieves First Overall Survival Benefit in Resistant Ovarian Cancer

1 week ago talkbio0Tagged checkpoint inhibitor, Co., KEYNOTE-B96 trial, Keytruda, Merck, ovarian neoplasm, Overall Survival, PD-L1, pembrolizumab, platinum-resistant, Progression-Free Survival

Merck & Co.; Keytruda; pembrolizumab; ovarian cancer; platinum-resistant; overall survival; checkpoint inhibitor; KEYNOTE-B96 trial; progression-free survival; PD-L1

Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for Neurotrophic Keratitis

1 week ago talkbio0Tagged gene therapy, HSV-1 viral vector, KB801, Krystal Biotech, Neurotrophic keratitis, platform technology designation, redesable eye drop, United States Food and Drug Administration, VYJUVEK

Krystal Biotech; FDA; platform technology designation; HSV-1 viral vector; KB801; gene therapy; neurotrophic keratitis; redesable eye drop; VYJUVEK

Novo throws weight behind budding rare disease pipeline

1 week ago talkbio0Tagged complement system, MASP-3 Inhibitor, Novo Nordisk, Omeros, Paroxysmal nocturnal hemoglobinuria, Payments, pipeline, Rare Diseases, Zaltenibart

Novo Nordisk; rare disease; pipeline; Omeros; Zaltenibart; MASP-3 inhibitor; PNH; complement system; milestone payments